Long-term AZT exposure alters the metabolic capacity of cultured human lymphoblastoid cells

Toxicological Sciences

Volumn 115, Issue 1, 2010, Pages 109-117

  Olivero, Ofelia A ^a   Vazquez, Irma L ^a   Cooch, Catherine C ^a   Ming, Jessica ^a   Keller, Emily ^a   Yu, Mia ^a   Borojerdi, Jennifer P ^a   Braun, Hannan M ^a   McKee, Edward ^b   Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretrovirals; Nucleoside analog; Thymidine kinase

Indexed keywords

THYMIDINE KINASE 1; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA; THYMIDINE; THYMIDINE KINASE;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL METABOLISM; CYTOTOXICITY; DNA DAMAGE; DRUG EXPOSURE; FLOW CYTOMETRY; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; METABOLIC CAPACITY; MICRONUCLEUS; MUTAGENESIS; RADIOIMMUNOASSAY; CELL CYCLE; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; DNA ADDUCT; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; MICRONUCLEUS TEST; PATHOLOGY; PHOSPHORYLATION; T LYMPHOCYTE; TUMOR CELL LINE;

ANTI-HIV AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA; DNA ADDUCTS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MICRONUCLEUS TESTS; PHOSPHORYLATION; T-LYMPHOCYTES; THYMIDINE; THYMIDINE KINASE; ZIDOVUDINE;

EID: 79953790499     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq023     Document Type: Article

References (40)

1. Agarwal, R. P., and Olivero, O. A. (1997). Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3'-azido-2',3'-dideoxythymidine (AZT). Mutat. Res. 390, 223-231.
2. Antonelli, G., Turriziani, O., Verri, A., Narciso, P., Ferri, F., D'Offizi, G., and Dianzani, F. (1996). Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res. Hum. Retroviruses 12, 223-228.
3. Arner, E. S., Spasokoukotskaja, T., and Eriksson, S. (1992). Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem. Biophys. Res. Commun. 188, 712-718.
4. Aruna, R., and Jagetia, G. C. (2001). Azidothymidine induces dose dependent increase in micronuclei formation in cultured HeLa cells. Pharmazie 56, 492-500.
5. Avramis, V. I., Kwock, R., Solorzano, M. M., and Gomperts, E. (1993). Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. J. Acquir. Immune Defic. Syndr. 6, 1287-1296.
6. Bishop, J. B., Witt, K. L., Tice, R. R., and Wolfe, G. W. (2004). Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage. Environ. Mol. Mutagen. 43, 3-9.
7. Dertinger, S. D., Torous, D. K., and Tometsko, K. R. (1996). Induction of micronuclei by low doses of azidothymidine (AZT). Mutat. Res. 368, 301-307.
8. Dobrovolsky, V. N., McGarrity, L. J., VonTungeln, L. S., Mittelstaedt, R. A., Morris, S. M., Beland, F. A., and Heflich, R. H. (2005). Micronucleated erythrocyte frequency in control and azidothymidine-treated Tk+/+, Tk+/-and Tk-/- mice. Mutat. Res. 570, 227-235.
9. Eriksson, S., Munch-Petersen, B., Johansson, K., and Eklund, H. (2002). Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 59, 1327-1346.
10. Furman, P. A., Fyfe, J. A., St Clair, M. H., Weinhold, K., Rideout, J. L., Freeman, G. A., Lehrman, S. N., Bolognesi, D. P., Broder, S., Mitsuya, H., et al. (1986). Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 83, 8333-8337.
11. Gonzalez, C. M., and Larripa, I. (1994). Genotoxicity of azidothymidine (AZT) in in vitro systems. Mutat. Res. 321, 113-118.
12. Groschel, B., Kaufmann, A., Hover, G., Cinatl, J., Doerr, H. W., Noordhuis, P., Loves, W. J., Peters, G. J., and Cinatl, J., Jr. (2002). 3'-Azido-2',3'-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells. Biochem. Pharmacol. 64, 239-246.
13. Han, T., Fernandez, M., Sarkar, M., and Agarwal, R. P. (2004). 2', 3'-Dideoxycytidine represses thymidine kinases 1 and 2 expression in T-lymphoid cells. Life Sci. 74, 835-842.
14. Hoever, G., Groeschel, B., Chandra, P., Doerr, H. W., and Cinatl, J. (2003). The mechanism of 3'-azido-2',3'-dideoxythymidine resistance to human lymphoid cells. Int. J. Mol. Med. 11, 743-747.
15. The International Agency for Research on Cancer. (2000). Some antiviral and antineoplastic drugs, and other pharmaceutical agents, Vol. 76, pp. 73-127. World Health Organization. International Agency for Research on Cancer, Lyon, France. Monographs on the Evaluation of Carcinogenic Risks to Humans.
16. Jacobsson, B., Britton, S., He, Q., Karlsson, A., and Eriksson, S. (1995). Decreased thymidine kinase levels in peripheral blood cells from HIVseropositive individuals: implications for zidovudine metabolism. AIDS Res. Hum. Retroviruses 11, 805-811.
17. Jacobsson, B., Britton, S., Tornevik, Y., and Eriksson, S. (1998). Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIVinfected individuals. Biochem. Pharmacol. 56, 389-395.
18. Kohler, J. J., Hosseini, S. H., Green, E., Hoying-Brandt, A., Cucoranu, I., Haase, C. P., Russ, R., Srivastava, J., Ivey, K., Ludaway, T., et al. (2008). Cardiac-targeted transgenic mutant mitochondrial enzymes: mtDNA defects, antiretroviral toxicity and cardiomyopathy. Cardiovasc. Toxicol. 8, 57-69.
19. McKee, E. E., Bentley, A. T., Hatch, M., Gingerich, J., and Susan-Resiga, D. (2004). Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc. Toxicol. 4, 155-167.
20. Meng, Q., Su, T., O'Neill, J. P., and Walker, V. E. (2002). Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger. Environ. Mol. Mutagen. 39, 282-295.
21. Mitsuya, H., Weinhold, K. J., Furman, P. A., St Clair, M. H., Lehrman, S. N., Gallo, R. C., Bolognesi, D., Barry, D. W., and Broder, S. (1985). 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 82, 7096-7100.
22. Mittelstaedt, R. A., Von Tungeln, L. S., Shaddock, J. G., Dobrovolsky, V. N., Beland, F. A., and Heflich, R. H. (2004). Analysis of mutations in the Tk gene of Tk(+/-) mice treated as neonates with 3'-azido-3'-deoxythymidine (AZT). Mutat. Res. 547, 63-69.
23. Munch-Petersen, B. (2009). Reversible tetramerization of human TK1 to the high catalytic efficient form is induced by pyrophosphate, in addition to tripolyphosphates, or high enzyme concentration. FEBS J. 276, 571-580.
24. Nyce, J., Leonard, S., Canupp, D., Schulz, S., and Wong, S. (1993). Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc. Natl. Acad. Sci. U.S.A. 90, 2960-2964.
25. Olivero, O. A. (2007). Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ. Mol. Mutagen. 48, 215-223.
26. Olivero, O. A., Beland, F. A., and Poirier, M. C. (1994). Immunofluorescent localization and quantitation of 3'-azido-2', 3'-dideoxythymidine (AZT) incorporated into chromosomal DNA of human, hamster and mouse cell lines. Int. J. Oncol. 4, 49-54.
27. Olivero, O. A., Ming, J. M., Das, S., Vazquez, I. L., Richardson, D. L., Weston, A., and Poirier, M. C. (2008). Human inter-individual variability in metabolism and genotoxic response to zidovudine. Toxicol. Appl. Pharmacol. 228, 158-164.
28. Olivero, O. A., Tejera, A. M., Fernandez, J. J., Taylor, B. J., Das, S., Divi, R. L., and Poirier, M. C. (2005). Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis 20, 139-146.
29. Perez-Perez, M. J., Priego, E. M., Hernandez, A. I., Familiar, O., Camarasa, M. J., Negri, A., Gago, F., and Balzarini, J. (2008). Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future. Med. Res. Rev. 28, 797-820.
30. Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., and Hirsch, M. S. (1987). The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 192-197.
31. Roskrow, M., and Wickramasinghe, S. N. (1990). Acute effects of 3'-azido-3'-deoxythymidine on the cell cycle of HL60 cells. Clin. Lab. Haematol. 12, 177-184.
32. Sherley, J. L., and Kelly, T. J. (1988). Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. J. Biol. Chem. 263, 375-382.
33. Stern, M., Cid, M. G., Larripa, I., and Slavutsky, I. (1994). AZT-induction of micronuclei in human lymphocyte subpopulations. Toxicol. Lett. 70, 235-242.
34. Turriziani, O., and Antonelli, G. (2004). Host factors and efficacy of antiretroviral treatment. New Microbiol. 27(Suppl. 1), 63-69.
35. Von Tungeln, L. S., Dobrovolsky, V. N., Bishop, M. E., Shaddock, J. G., Heflich, R. H., and Beland, F. A. (2004). Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine. Mutagenesis 19, 307-311.
36. Witt, K. L., Tice, R. R., Wolfe, G. W., and Bishop, J. B. (2004). Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment. Environ. Mol. Mutagen. 44, 321-328.
37. Wu, S., Liu, X., Solorzano, M. M., Kwock, R., and Avramis, V. I. (1995). Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8, 1-9.
38. Wu, Y. W., Xiao, Q., Jiang, Y. Y., Fu, H., Ju, Y., and Zhao, Y. F. (2004). Synthesis, in vitro anticancer evaluation, and interference with cell cycle progression of N-phosphoamino acid esters of zidovudine and stavudine. Nucleosides Nucleotides Nucleic Acids 23, 1797-1811.
39. Yarchoan, R., Mitsuya, H., Myers, C. E., and Broder, S. (1989). Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321, 726-738.
40. Yu, M., Ward, Y., Poirier, M. C., and Olivero, O. A. (2009). Centrosome amplification induced by the antiretroviral nucleoside reverse transcriptase inhibitors lamivudine, stavudine, and didanosine. Environ. Mol. Mutagen. 50, 718-724.